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Abstract
Introduction: It is postulated that breast cancer stem cells (bCSCs) mediate disease recurrence and drive formation
of distant metastases - the principal cause of mortality in breast cancer patients. Therapeutic targeting of bCSCs,
however, is hampered by their heterogeneity and resistance to existing therapeutics. In order to identify strategies
to selectively remove bCSCs from breast cancers, irrespective of their clinical subtype, we sought an apoptosis
mechanism that would target bCSCs yet would not kill normal cells. Suppression of the apoptosis inhibitor cellular
FLICE-Like Inhibitory Protein (c-FLIP) partially sensitizes breast cancer cells to the anti-cancer agent Tumour Necrosis
Factor-Related Apoptosis Inducing Ligand (TRAIL). Here we demonstrate in breast cancer cell lines that bCSCs are
exquisitely sensitive to the de-repression of this pro-apoptotic pathway, resulting in a dramatic reduction in
experimental metastases and the loss of bCSC self-renewal.
Methods: Suppression c-FLIP was performed by siRNA (FLIPi) in four breast cancer cell lines and by conditional
gene-knockout in murine mammary glands. Sensitivity of these cells to TRAIL was determined by complementary
cell apoptosis assays, including a novel heterotypic cell assay, while tumour-initiating potential of cancer stem cell
subpopulations was determined by mammosphere cultures, aldefluor assay and in vivo transplantation.
Results: Genetic suppression of c-FLIP resulted in the partial sensitization of TRAIL-resistant cancer lines to the pro-
apoptotic effects of TRAIL, irrespective of their cellular phenotype, yet normal mammary epithelial cells remained
refractory to killing. While 10% to 30% of the cancer cell populations remained viable after TRAIL/FLIPi treatment,
subsequent mammosphere and aldefluor assays demonstrated that this pro-apoptotic stimulus selectively targeted
the functional bCSC pool, eliminating stem cell renewal. This culminated in an 80% reduction in primary tumours
and a 98% reduction in metastases following transplantation. The recurrence of residual tumour initiating capacity
was consistent with the observation that post-treated adherent cultures re-acquired bCSC-like properties in vitro.
Importantly however this recurrent bCSC activity was attenuated following repeated TRAIL/FLIPi treatment.
Conclusions: We describe an apoptotic mechanism that selectively and repeatedly removes bCSC activity from
breast cancer cell lines and suggest that a combined TRAIL/FLIPi therapy could prevent metastatic disease
progression in a broad range of breast cancer subtypes.
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Recognition that breast cancer is a heterogeneous disease
has helped shape advances in therapy, leading to more tar-
geted therapeutic strategies and improved survival rates in
discrete disease subgroups [1]. This is exemplified by the
advent of therapeutic agents targeting estrogen-receptor
positive (ER
+) and HER2-positive (HER2
+) breast cancers,
which make up approximately 70% of all breast tumours
[2,3]. Despite these improvements, however, tumours
often relapse due to innate or acquired resistance to the
therapeutic insult. At the centre of this problem lies addi-
tional tumour heterogeneity whereby a small population
of cells within, or possibly outside, the tumour are both
resistant to drugs and provide the source of new tumour
growth [4,5]. These cells also contribute directly to the
seeding of secondary tumours at distal sites, the primary
cause of mortality in breast cancer patients [6]. These
drug resistant cancer initiating cells, often referred to as
breast Cancer Stem Cells (bCSCs), have been demon-
strated functionally for both human and mouse mammary
tumours and tumour cell lines [7-13]. Experiments on
human breast tumours in mouse models, for example,
indicate that when these cells were deleted, the remaining
cells were unable to sustain new tumour growth
[11,13,14]. There is, therefore, considerable interest in tar-
geting CSCs within tumours with cytotoxic agents as a
cure for breast and other cancers and where possible to
broaden the specificity of therapeutic agents to treat as
wide a patient group as possible.
Tumour Necrosis Factor (TNF)-Related Apoptosis Indu-
cing Ligand (TRAIL) is a promising anticancer agent that
exhibits tumour specificity with only mild side effects
observed in clinical trials for the treatment of colorectal
cancer, non-small cell lung carcinoma and non-Hodgkins
lymphoma [15,16]. In breast cancer, however, its therapeu-
tic potential is limited by the fact that the majority of
breast cancer cell types are resistant to TRAIL [17,18].
This has prompted much interest in identifying agents
that might increase TRAIL sensitivity in a larger cohort of
breast cancer patients. Moreover, stem cells, including
cancer stem cells, are documented to be resistant to
TRAIL [16,19,20], suggesting that without further sensiti-
zation of the tumour-initiating cell sub-population,
patients are likely to relapse following TRAIL therapy.
TRAIL targets tumour cells for instructive cell death
via the cell-surface receptors TRAIL-R1 (DR4) and
TRAIL-R2 (DR5), which initiate the formation of death
inducing signalling complexes (DISCs) ultimately leading
to the activation of the caspase cascade [21]. A number
of studies have described agents that sensitize one or
more breast cancer subtypes to TRAIL, the majority of
which implicate components of the apoptosis regulatory
machinery as the underlying causes of sensitization
[22-35]. Common to a number of these studies is the
observation that the endogenous inhibitor of death
receptor killing, cellular FLICE-Like Inhibitory Protein
(c-FLIP), is down-regulated during the sensitization pro-
cess [22,26,28,30-32,34]. c-FLIP is a non-redundant
antagonist of caspases -8 and -10, preventing these cas-
pases from binding to the DISC and thus inhibiting
autolytic cleavage and subsequent activation of down-
stream executioner caspases [36] following stimulation
by TRAIL. The suppression of c-FLIP has been shown
to sensitize some breast cancer cell lines to TRAIL
mediated killing, raising the possibility that such a
mechanism could be targeted in breast cancer patients
[22,31,32,37-39]. However, several questions concerning
the specificity of c-FLIP in breast cancer remain that
would significantly impact on its prospects as a therapy
for breast cancer. These include: whether suppressing c-
FLIP in non-tumour cells compromises their viability;
whether a broad range of breast cancer subtypes are
affected by c-FLIP sensitization; and of particular clinical
significance, whether the normally chemo-resistant CSC
sub-populations within each of these heterogeneous sub-
types are sensitive to de-repression of this apoptotic
pathway.
Here we addressed each of these clinically relevant
questions by selectively targeting c-FLIP in pre-clinical
models of breast cancer. We looked at the effects of sup-
pressing c-FLIP in non-tumourgenic cells, and showed
that c-FLIP exhibited tumour cell specificity, similar to
that previously ascribed to TRAIL in other tumour types
[15,40,41]. Moreover, we demonstrated that the de-
repression of TRAIL by c-FLIP inhibition selectively
eliminated breast cancer stem cells (bCSCs) from tumour
cell populations, irrespective of their HER2/ER receptor
status and despite CSC plasticity within the surviving
tumour cell population. These observations were then
confirmed in in vivo models of breast cancer whereby
primary tumourgenesis was reduced by 80% and the
seeding of new tumour growth at distal sites, leading to
metastatic disease, was almost completely inhibited.
These findings demonstrate potent cellular responses to
TRAIL sensitization that have important clinical implica-
tions for the advent of new therapeutic strategies for
breast cancer patients.
Materials and methods
All experiments were performed with the approval of the
University of Cardiff School of Biosciences Ethics Com-
mittee and animal work was performed in accordance
with the Home Office Animals (Scientific Procedures)
Act 1986 under project licence 30/2849.
Cell culture
Four human breast cancer cell lines BT474
ER+HER2+,
SKBR3
ER-HER2+, MCF-7
ER+HER2-, MDA-MB-231
ER-HER2-;
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P-L Lollini, Sezione di Cancerologia, Bologna, Italy); the
non-tumourigenic cell lines human MCF10A (from T.
Stein, University of Glasgow, UK) and murine EPH4
(from C. Watson, University of Cambridge, UK) were
maintained in DMEM (MDA-MB-231, EPH4), or RPMI
1640 medium (SKBR3, MCF-7 and BT-474), supplemen-
ted with 10% foetal bovine serum, 1% penicillin-strepto-
mycin and 0.5% L-glutamine at 37°C in 5% CO2.
Monolayer MCF10A cells were cultured in DMEM/F12,
5% horse serum, 20 ng/ml EGF, 0.5 mg/ml hydrocorti-
sone, 100 ng/ml cholera toxin, 10 μg/ml insulin.
siRNA
Small interfering RNAs (siRNA) targeting two unique
sequences in human c-FLIP (FLIPi - Sense: GGAUAAAU-
CUGAUGUGUCCUCAUUA, Anti-Sense: UAAUGAGGA
CACAUCAGAUUUAUCC) and a non-specific scrambled
c o n t r o l( S C i-S e n s e :G G ACUAAUAGUUGUGCUC-
CAAUUUA, Anti-Sense: UAAAUUGGAGCACAACUAU
UAGUCC) RNA were used in reverse transfections (Invi-
trogen Life Technologies Ltd, Paisley, UK). Cells were
trypsinised and resuspended at a density of 1 × 10
5 cells/
ml and seeded into wells containing 20 μlo f1 0 0n M
siRNA in serum free Optimem (Invitrogen Life Technolo-
gies Ltd, Paisley, UK)) in a volume of 100 μlp e rw e l l
together with 0.3 μl of Lipofectamine (Invitrogen Life
Technologies Ltd). Cells were cultured in the presence of
siRNA for 48 hours (MCF-7, MCF10A, EPH4, N202.1A
and MDA-MB-231) or 72 hours (SKBR3 and BT474) prior
to subsequent assay.
TRAIL treatment of target cells
Cells were treated with soluble human recombinant
TRAIL (SuperKillerTRAIL, Enzo Life Sciences, Exeter,
UK) at a concentration of 20 ng/ml for 18 hours at 37°C
in 5% CO2. For mouse target cells, soluble mouse recom-
binant TRAIL (Enzo Life Sciences) was added at a con-
centration of 100 ng/ml for 18 hours.
Western blot assays
Western blots of cell lysates were performed using the
following antibodies: cFLIP (Enzo Life Sciences, NP6,
ALX-8040428), ER a (Santa Cruz Biotechnology, Santa
Cruz, CA, USA, sc-7207), ErbB2 (Abcam, Cambridge,
UK, ab2428), Tubulin (Abcam, ab6160).
In vitro caspase inhibition
Functional blocking of caspases was assessed by co-incu-
bation of cells with siRNA and the caspase inhibitors
IETD (1 μM), LEHD (10 μM) and AEVD (10 μM) (R&D
Systems, Abingdon, Oxford, UK) to inhibit caspases 8, 9
and 10 respectively. After 48 to 72 hours co-incubation,
cells were analysed using Annexin-V APC apoptosis
assay (eBioscience Ltd, Hatfield, UK).
Cell viability and cell death assays
In heterotypic cell culture assays: siRNA treated cells
were treated with 0.25% trypsin for 10 minutes, washed
and stained with PKH67 or PKH26 (Sigma-Aldrich, Gil-
lingham, Dorset, UK). PKH67+ve FLIPi cells and PKH26
+ v eS C ic e l l sw e r em i x e d1 : 1a n dc u l t u r e do v e r n i g h t
with or without TRAIL and subsequently resuspended
in 4 μl of 1:10 fixable near-IR live/dead stain (Invitro-
gen) and incubated for 15 minutes at 4°C. Cells were
then gated for PKH staining versus live/dead staining
using a FACS Canto (Becton Dickinson, Oxford, UK).
For detailed protocol, see supplementary data. In homo-
typic cell culture assays: CellTiter blue cell viability
assay (Promega UK Ltd, Southampton, UK) and Cas-
pase-Glo assay (Promega) were performed according to
the manufacturer’s instructions and fluorescence/absor-
bance/luminescence was assessed using a FluoStar
Optima plate reader, while annexin-V APC labelled cells
(eBioscience) were analysed by FACS Canto.
Mouse mammary gland tissue histology and primary
culture
All procedures were performed in accordance with the
Animals (Scientific Procedures) Act 1986 and approved by
t h eU KH o m eO f f i c e .c - F L I P
fl/fl mice [42] were crossed
with blg-Cre animals [43] to conditionally delete c-FLIP
from mammary epithelium. Mammary tissues from 12-
week old and 14-day pregnant blg-Cre/c-FLIP
fl/fl females
and blg-Cre/c-FLIP
+/+ littermate controls were harvested
and fixed in 4% paraformaldehyde/PBS (pH 7.4) overnight,
and embedded in paraffin. Paraffin sections (5 μm) were
placed on slides, de-waxed and stained with H&E. For pri-
mary cell culture, mid-pregnant animals were sacrificed
and abdominal mammary glands excised and washed in
70% ethanol. Lymph nodes were removed and finely
minced tissue was then processed as described [44]. Pri-
mary cells were maintained in 5% CO2,5 %O 2 at 37°C.
Mammosphere culture
Cell lines were dissociated into single cell suspensions
and plated in ultra-low attachment plates (Corning Life
Sciences, Amsterdam, Netherlands) at a density of 20,000
cells/ml in a serum-free epithelial growth medium
(MEBM, Lonza Walkersville, MD, USA), supplemented
with B27 (Invitrogen), 20 ng/ml EGF (Sigma-Aldrich),
Insulin (Sigma-Aldrich), b-mercaptoethanol and hydro-
cortisone. After seven days mammospheres were col-
lected by gentle centrifugation (1,100 rpm), dissociated in
0.05% trypsin, 0.25% EDTA and re-seeded at 10,000
cells/ml for subsequent passages.
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Surviving cell populations were harvested in 0.25% tryp-
sin and collected by gentle centrifugation (1,100 rpm).
Cell pellets were then washed twice in PBS prior to
Aldefluor assay (Stem Cell Technologies, Grenobles,
France) as previously described [45].
Mouse tumourigenicity assays
In vivo tumour initiating capability of siRNA treated cells
was assessed by orthotopic mammary fat pad transplan-
tation and tail vein injections of BT474 and MDA-MB-
231 cell lines, respectively. BT474 siRNA treated cells
were harvested using 1 mM EDTA, washed and resus-
pended at a density of 5 × 10
6 cells/ml in serum-free L15
media. A 1.5 mg, 60-day slow release 17-b estradiol pellet
(Innovative Research of America, Sarasota FL, USA) was
inserted subcutaneously above the right scapula of anaes-
thetised athymic nude mice. A total of 1 × 10
6 cells were
orthotopically injected directly into the abdominal mam-
mary fat pad, with or without 100 ng/ml TRAIL. Mice
were then monitored, and when palpable, tumour volume
measured twice weekly. MDA-MB-231 cells treated with
siRNA were harvested and prepared for injection in the
same manner as BT474 cells. Cells were then injected
into the mouse tail vein, with or without TRAIL in a
volume of 200 μl and mice were sacrificed six weeks
post-injection.
Statistical methods
Throughout the article, data are represented as mean +/-
standard error taken over a minimum of three indepen-
dent experiments, unless otherwise stated. Statistical sig-
nificance was measured using parametric testing,
assuming equal variance, in the majority of experiments
with standard t tests for two-paired samples used to assess
difference between means.
Results
c-FLIP deficiency exhibits tumour cell specificity in
mammary epithelium
It has been reported that TRAIL preferentially targets
tumour cells over normal cells [15,40,41]. To determine
if the targeted inhibition of c-FLIP exhibited similar spe-
cificity for tumour cells, mammary epithelial cell viability
was assessed in non-tumourgenic c-FLIP-deficient mouse
mammary glands, transformed murine cell lines and in
the human breast cell line MCF-10A. c-FLIP was condi-
tionally deleted from mammary epithelial cells of juvenile
mice by crossing the blg-Cre transgene [43] into the c-
FLIP
fl/fl line [42], and the mammary epithelial compart-
ment subsequently assessed in adult virgin and pregnant
animals. Mammary epithelial morphogenesis and cell
number in blg-Cre/c-FLIP
fl/fl mammary glands was indis-
tinguishable from wild-type controls, while isolated
primary epithelial cells from both genetic backgrounds
exhibited comparable cell viability either in the presence
or absence of TRAIL in vitro (Figure 1A, B). Further-
more, inhibition of c-FLIP (FLIPi) using murine specific
siRNA had no effect on a non-tumourgenic murine cell
line’s response to TRAIL but significantly reduced viabi-
lity in a tumourgenic line (Figure 1C). Similarly, in the
human non-tumourgenic breast cell line, MCF-10A, cell
viability was unaffected by c-FLIP inhibition (FLIPi)
alone; however, combined treatment with TRAIL
induced a significant cell death response (Figure 1D),
confirming previous reports of TRAIL sensitivity in
human transformed cell lines [27]. These data indicate
that the targeted inhibition of c-FLIP exhibited tumour
specific effects, similar to those observed with TRAIL in
other cancer types.
Suppression of c-FLIP (FLIPi) sensitized breast cancer cell
lines irrespective of hormone receptor status
Whilst most breast cancers are resistant to TRAIL induced
apoptosis, it has recently been reported that mesenchymal
breast cancer cell lines that lack hormone receptors
(HER2 and ERa) respond to TRAIL treatment [18]. This
is a clinically important subgroup of breast cancer, yet it
represents only 20 to 25% of the breast cancer patient
population. In order to establish the extent to which c-
FLIP might broaden the specificity of TRAIL-induced
cytotoxicity, we wanted to directly compare the relative
sensitivity of different breast cancer subtypes to the com-
bined effects of c-FLIP inhibition and TRAIL treatment.
We selected four breast cancer cell lines representing
all combinations of ERa and HER2 expression: the lumi-
nal-like cells BT474
ER+HER2+, SKBR3
ER-HER2+ and MCF-7
ER+HER2-, which represent the majority of breast cancers
and the basal-like cell line MDA-MB-231
ER-HER2- [46].
Having confirmed their receptor status (Additional file 1
Figure S1) and TRAIL sensitivity in 2D-adherent cell cul-
ture (Figure 2A), the effect of inhibiting c-FLIP expres-
sion (FLIPi) on cell viability was tested in each cell line
using a novel fluorescent heterotypic cell culture assay
(Additional file 1 Figure S2). Both c-FLIPS and cFLIPL
transcripts were inhibited by siRNA, resulting in a greater
than 70% decrease in expression of c-FLIP in all cell lines
(Additional file 1 Figure S3). The suppression of c-FLIP,
which had no effect on DR4 or DR5 expression (Addi-
tional file 1 Figure S3C), significantly decreased cell viabi-
lity by 10 to 15% in all of the breast tumour cell lines
tested (Figure 2B, black bars). This was confirmed to be
apoptosis by annexin-V staining and through the use of
caspase inhibitors that restored cell viability in a cell
dependent manner (Additional file 1 Figure S4).
When c-FLIP inhibition (FLIPi) was combined with
TRAIL administration, a significant TRAIL-dependent
kill was observed for all of the breast cancer cell lines
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S5), demonstrating a marked sensitization to TRAIL in
resistant cell lines, but no more than an additive effect
of FLIPi in the TRAIL-sensitive MDA-MB-231 cell line.
Thus, TRAIL/FLIPi had a marked effect on breast can-
cer cell viability irrespective of hormone receptor status.
Despite the significant sensitization to TRAIL, between
8% (MDA-MB-231) and 33% (MCF-7) of the cell popu-
lations survived the combined (TRAIL/FLIPi) treatment
(Figure 2C), which suggested a differential response to
this apoptotic insult by these heterogeneous cell
populations.
FLIPi sensitized breast cancer stem cells (bCSCs) to TRAIL
Breast tumours and breast cancer cell lines, contain a
small sub-population (up to 2%) of tumour initiating
(cancer stem) cells [8]. These cells have been shown to
be resistant to existing chemotherapeutic agents [47].
We wished to establish whether the cells surviving the
TRAIL/FLIPi treatment within each cell line (Figure 2C)
included a resistant sub-population of breast cancer
stem cells (bCSCs).
The proportion of bCSCs in each of the cell line’s sur-
viving cell population was determined using the func-
tional mammosphere formation assay, as previously
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Figure 1 FLICE-Like Inhibitory Protein (c-FLIP) suppression does not induce cell death in non-tumourigenic mammary cells. A,
Haematoxylin/eosin-stained sections of mouse mammary glands excised from virgin or 14-day gestating b-lactoglobulin(BLG)-Cre/c-FLIP
+/+ or
BLG-Cre/c-FLIP
fl/fl animals. Pictures are representative of four animals per group. B, Mammary epithelial cells isolated from BLG-Cre/c-FLIP
fl/fl (Flip-
floxed) and c-FLIP
+/+ (WT) animals were grown in primary cell culture and incubated in the presence or absence of 100 ng/ml of soluble
(mouse) Tumour Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) for 18 hours. Cell viability was analysed using cellTiter blue viability
assay. C, EPH4 (non-tumourgenic) and N202.1A (tumourgenic) cells were transfected with FLIP siRNA (FLIPi) or control siRNA (SCi) for 48 hours,
media was then removed and fresh media with or without 100 ng/ml of mouse TRAIL was added for 18 hours and cell death assessed by flow
cytometry as described in methods. D, MCF10A (non-tumourgenic) cells were treated and assayed according to C using 20 ng/ml human TRAIL.
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c-FLIP RNAi prior to transfer of viable cells to non-
adherent conditions, whereupon cells were treated with
TRAIL. Each of the untreated cell lines formed mam-
mospheres of distinct size and morphology with the ER
+ve lines, BT474 and MCF7, forming the largest, most
uniform colonies (Figure 3A) and the ER-ve lines,
SKBR3 and MDA-MB-231 forming loose, irregular colo-
nies, as previously demonstrated [9]. Suppression of c-
FLIP alone had no discernable effect on mammosphere
integrity while TRAIL treatment alone partially impaired
MCF-7 and MDA-MB-231 mammosphere morphology.
Combined treatment, however, severely disrupted mam-
mosphere formation in all four cell lines. This was con-
firmed by quantification of mammosphere forming units
(MFUs) in short-term culture and serial passage (Figure
3B) whereby all self-renewing MFUs were deleted from
the cell populations.
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Figure 2 Suppression of c-FLIP sensitises breast cancer cell lines to TNF-Related Apoptosis Inducing Ligand (TRAIL). A, Cell lines were
incubated with 20 ng/ml soluble TRAIL for 18 hours and cell viability assessed by cellTiter Blue viability assay. Viability is shown as a percentage
of the untreated controls for each cell line (*: P < 0.01, n = 3). B, PKH67-stained cells pre-treated with c-FLIP siRNA and PKH26-stained cells pre-
treated with control siRNA were mixed and co-cultured for 18 hours in complete media +/-20 ng/ml TRAIL, and assessed by flow cytometry for
live/dead cells (see Supplementary figure S2). The percentage increase in cell death of cFLIP siRNA cells compared to their scrambled siRNA
controls were plotted for each of the cell lines. TRAIL-treated co-cultures (white bars) and TRAIL-untreated co-cultures (Black bars) were plotted
separately. Each co-culture was repeated in three independent experiments. + = P < 0.01, for percentage increase in cell death between c-FLIP
siRNA and scrambled siRNA control. * = P < 0.01, for difference in c-FLIP siRNA mediated death between TRAIL-treated and untreated co-
cultures. C, Cells were treated as in B and gated to give the percentage of remaining live cells after treatment. FT = c-FLIP siRNA.
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Figure 3 FLIPi/TRAIL treatment inhibits mammosphere formation and prevents self-renewal of mammosphere forming units. A,
Following c-FLIP siRNAi (FLIPi) or control siRNA (SCi) transfection, cell lines were plated in low-serum non-adherent culture conditions in the
presence or absence of 20 ng/ml TRAIL at a density of 4,000 cells per well (20,000 cells/ml). Pictures are representative of mammosphere
forming units (MFU) observed. B, Mammospheres from three replicate wells per condition were counted following seven days culture (Passage
1). Mammospheres were dissociated using trypsin, passaged at a density of 2,000 cells/well (10,000 cells/ml) in the absence of TRAIL and
counted after seven days culture (Passage 2). Results are calculated as a percentage of mammosphere forming units from the total number of
cells seeded and are representative of three independent experiments. C, siRNA-transfected SKBR3 and BT474 cells were treated +/- 20 ng/ml
TRAIL for 18 hours, surviving adherent monolayers were then assessed for aldefluor activity by flow cytometry. Graph represents the percentage
of cells scoring positive for aldefluor activity in three independent experiments (* P < 0.01 vs. SCi control).
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untreated cell lines ranged from 0.4% to 1.4% of the total
cell populations. SKBR3 and MCF-7 MFUs were partially
sensitive to TRAIL induced anoikis, as less than a quarter
of the mammospheres formed in the presence of TRAIL
alone during the first passage (Figure 3B, Passage 1). Simi-
larly SKBR3, but not MCF-7, MFUs were significantly
depleted with FLIPi treatment alone whilst MDA-MB-231
and BT474 cells were completely resistant to either FLIPi
or TRAIL treatment alone. In all cases, however, sensitivity
to anoikis was dramatically enhanced with combined
treatment. From starting populations of 12,000 cells, no
mammospheres survived in MDA-MB-231 and BT474
cultures, while two and one loose-forming colonies,
respectively, were evident in SKBR3 and MCF-7 cells.
Serial passaging of mammospheres in the absence of
TRAIL and/or FLIPi revealed enrichment of MFUs in all
cell cultures except those pre-treated with both TRAIL
and FLIPi (Figure 3B). MFU enrichment is indicative of
stem cell self-renewal due to symmetric cell division [8].
The complete loss of mammospheres from TRAIL/FLIPi
treated cultures in subsequent passages suggests that the
few surviving cancer initiating cells from 18 hours com-
bined treatment were severely compromised and unable to
undergo additional symmetric cell divisions. The same
results were also observed using an alternative c-FLIP
siRNA target sequence (Additional file 1 Figure S6).
The ablation of functional MFUs represents a preferen-
tial sensitization of bCSCs to TRAIL compared to the rest
of the tumour cell population. This was confirmed by flow
cytometry using the marker ALDH1 that has previously
been shown to enrich HER2-positive breast cancer cell
populations for tumour initiating cells (Additional file 1
Figure S7) [48]. The HER2-positive cell lines BT474 and
SKBR3 were subjected to TRAIL/FLIPi or control siRNA
(SCi) for 18 hours and only the surviving adherent cells
stained for ALDH1 activity. Both cell lines exhibited signif-
icant reductions in the relative proportion of ALDH1 posi-
tive cells in the surviving populations following combined
treatment (Figure 3C).
In order to address which c-FLIP isoform was responsi-
ble for the ablation of the self-renewing activity of the can-
cer stem cell population, siRNA sequences specific for
cFLIP-short and c-FLIP-long transcripts were used prior
to mammosphere assay. Silencing of c-FLIP-long, but not
c-FLIP-short, mimicked the cytotoxic effects of global c-
FLIP suppression in cancer stem cells, which confirmed an
earlier observation of c-FLIP-long mediated survival in
MCF-7 cells (Figure 4). Suppression of c-FLIP isoforms
also sensitized cancer stem cells to sub-toxic levels of
TRAIL (Figure 5). TRAIL concentrations were reduced
from 20 ng/ml to 1 ng/ml, levels that failed to activate a
cell death response in the TRAIL-sensitive MDA-MB-231
cell line (Figure 5A), and mammosphere cultures were
performed as described above. TRAIL addition alone had
reduced effects on mammosphere integrity, yet combined
treatment abrogated MFUs in BT474, SKBR3 and MDA-
MB-231 cell cultures, as previously observed with higher
concentrations of TRAIL. The poorest responding cells to
combined treatment, MCF-7 (Figure 3B), developed self-
renewing MFUs at very low frequency (1/12,000 cells
seeded) in reduced TRAIL conditions (Figure 5A).
The mammosphere formation assay primarily tests the
cells’ ability to resist anoikis, which is a key property of
tumour initiating (cancer stem) cells. As c-FLIP has pre-
viously been reported to be an inhibitor of anoikis in other
tumour cell types [49] we wished to test whether the MFU
sensitization to TRAIL was dependent on the additional
stresses imparted by the non-adherent conditions (Figure
5B). Each of the cell lines was subjected to c-FLIP RNAi
and then incubated with TRAIL for 18 hours in adherent
culture, as previously performed in the viability assays
(Figure 1). Viable cells were subsequently washed and pla-
ted in non-adherent, mammospheres culture for seven
days, in the absence of TRAIL, and the number of mam-
mospheres counted. The self-renewing capacity of MFUs
was once again abolished in MCF7, MDA-MB-231 and
BT474 cell lines although SKBR3 cells exhibited a residual
MFU self-renewal capacity. Thus while some cell lines
exhibited reduced sensitivity to combined treatment when
maintained in nurturing conditions, all continued to dis-
play a significant reduction in CSC properties.
Tumour initiation and metastatic progression were
compromised by combined TRAIL/cFLIPi treatment
In order to confirm that the loss of MFUs was consis-
tent with a reduction in tumour initiating capacity,
adherent cultures of BT474 cells were treated with c-
FLIP siRNA and 10
6 viable cells orthotopically trans-
planted into the mammary glands of immune-compro-
mised mice in the presence or absence of TRAIL
(Figure 6A). The occurrence of palpable tumours was
monitored for up to 16 weeks after transplantation.
Tumours arose at the site of transplantation within
eight weeks (Additional file 1 Figure S8A) of surgery in
all mice transplanted with either untreated BT474 or
FLIPi-treated BT474 cells, while three out of five mice
with TRAIL-treated BT474 transplants acquired
tumours in the same time-frame. However, four out of
five transplants co-treated with FLIPi and TRAIL failed
to acquire tumours within 16 weeks of surgery (Figure
6A). Tumour growth and histology were unaffected in
all conditions.
This residual tumour initiating capacity following com-
bined treatment occurred despite complete loss of
self-renewing mammosphere forming potential in vitro
(Additional file 1 Figure S8B). In order to determine
whether this tumour initiating potential was re-acquired
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TRAIL/FLIPi treated cultures - with no residual mammo-
sphere forming ability (Figure 6B, Treatment 1)-w e r e
maintained in adherent culture for four weeks then trans-
ferred to mammosphere culture or re-treated with
TRAIL/FLIPi (Figure 6B, Treatment 2). The surviving
population slowly re-populated the adherent conditions
(Additional file 1 Figure S8C) and re-acquired an equiva-
lent proportion of mammospheres to the original
untreated population (compare SCi samples, Figure 6B,
Treatments 1 and 2). However, this subset of self-renew-
ing cells was still exquisitely sensitive to TRAIL/FLIPi, as
combined treatment of the re-established adherent cul-
tures once again eradicated MFUs from the cell popula-
tion (Figure 6B, Treatment 2).
Cancer stem cells are thought to be responsible for
the seeding of new tumour growth at distal sights,
which is central to the progression of metastatic disease
- the major cause of mortality in breast cancer patients.
We used an established in vivo model of breast cancer
metastasis, intravenous transplantation of MDA-MB-231
cells, to determine the effect of TRAIL/FLIPi on disease
progression. Adherent cultures of MDA-MB-231 cells
were treated with c-FLIP siRNA (or control) and 10
6
viable cells transplanted intravenously into immune-
compromised mice in the presence or absence of TRAIL
(Figure 6C). After six weeks the number of lung metas-
tases was determined by dissection and serial section of
lung tissues from recipient mice. An average of 23 sec-
ondary tumours per mouse were found in animals trans-
planted with control cells, compared to an average of
0.4 tumours (a total of two micrometastases from five
mice) in transplants subjected to TRAIL and FLIPi. This
represented a 98% reduction in tumour burden and a
significant sensitization of TRAIL mediated suppression
of metastatic disease (Figure 6C).
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Figure 6 FLIPi/TRAIL inhibits tumour initialisation and metastatic potential in vivo. A, BT474 cells were transfected with c-FLIP siRNA (FLIPi)
or control siRNA (SCi) and 1 × 10
6 cells orthotopically transplanted in the presence or absence of 100 ng/ml TRAIL into the abdominal
mammary fat pad of athymic nude mice in the presence of systemic estradiol. Transplant sites were monitored and measurements of palpable
tumours taken twice weekly. B, FLIPi-transfected BT474 cells were treated for 18 hours with 20 ng/ml of TRAIL, the surviving adherent cells were
then harvested and re-plated either in mammosphere culture (TRAIL/FLIPi Treatment 1) or adherent conditions at a density of 20,000 cells/ml.
After four weeks culture, the adherent cell cultures were re-treated with FLIPi or SCi and 20 ng/ml TRAIL (18 hours) before plating for
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6 FLIPi (FT) or SCi (SC)
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Mice were monitored daily and sacrificed six weeks post-surgery for histological examination of lung metastases.
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Tumour heterogeneity is a major obstacle to therapy.
Recent insights into the hierarchical organisation of
tumour cell populations highlights the potential impor-
tance of targeting the minority tumour-initiating (cancer
stem) cell population associated with cancers in order to
radically improve patient outcome. The problem is that
cancer stem cells are inherently resistant to chemothera-
peutic challenge.
Here we have shown, using complementary in vitro and
in vivo functional assays, that inhibition of c-FLIP (FLIPi)
overcomes resistance of breast cancer stem cells (bCSCs)
to the anti-cancer agent TRAIL, resulting in the selective
elimination of stem cell characteristics in all of the cell
lines tested, independent of hormone receptor status.
This potentially broadens the range of breast cancer sub-
t y p e st h a tc o u l db e n e f i tf r o maT R A I L - b a s e dt h e r a p y
[18]. Formation of the DISC is a limiting factor in the
initiation of the extrinsic apoptotic cascade [50,51]. We
have confirmed that c-FLIP antagonises this cascade
through the inhibition of either of the extrinsic initiator
caspases, which cross-talk to the intrinsic pathway (cas-
pase 9) [38]. The ability to de-repress either caspase-8 or
-10 via FLIPi helps to explain the broad range of breast
cancer cell types affected.
W ef o u n dt h a tc o m b i n e dT R A I L / F L I P it r e a t m e n tex-
vivo had a marked impact on tumour seeding in vivo,
resulting in a comprehensive suppression of lung metas-
tases arising from circulating tumour cells (Figure 6). Sig-
nificantly this occurred when TRAIL was co-injected with
cells that had previously not been subjected to TRAIL
while in cell culture. Despite this, however, a residual
tumour initiating capacity persisted in the TRAIL/FLIPi
cohort. This may be explained by our in vitro observations
suggesting that bCSCs were marginally more resistant
(Figure 5) and exhibited cellular plasticity (Figure 6B) in
the nurturing microenvironment of adherent culture. The
observation of functional plasticity in mammosphere cul-
ture supports a previous study using surrogate markers of
bCSCs in breast cancer cell lines [52]. Crucially, however,
we show that the newly acquired MFU activity remained
responsive to re-administration of TRAIL/FLIPi. A similar
sensitivity to repeat treatments has previously been
observed for the Akt inhibitor perifosine, in a xenograft
model of Sum159 cells [45]). These observations have
important implications for the future prevention of disease
relapse in the clinical setting as they demonstrate that the
tumourigenic cell population may be targeted without
selecting for resistant cells.
It has been suggested that tumour cells in their nat-
ural context do not necessarily exhibit the sensitivity to
TRAIL monotherapy as observed in vitro,i m p l y i n gt h a t
a combined therapy would be required to re-sensitize to
TRAIL [53]. We have used RNAi to demonstrate the
proof of principle that suppression of c-FLIP expression
in combination is sufficient to sensitize breast cancer
c e l l st oT R A I L .I nl i g h to ft h i s ,ak e yf u t u r eo b j e c t i v ei s
to establish whether long-term suppression of c-FLIP in
vivo - perhaps following the cessation of TRAIL treat-
ment - might help prevent the recurrence of tumours.
Despite limitations in drug design due to structural
homology between c-FLIP and caspases, agents with
broad specificity for c-FLIP have been described, each
with anti-tumour properties [22,26,28,30,54,55]. It
remains to be determined if these agents exhibit selec-
tive targeting of cancer stem cells and whether this is
recapitulated in vivo in the absence of off target effects.
The breadth of the breast tumour cell types affected
here raises the question of the potential ubiquity of
FLIPi/TRAIL treatment in targeting other cancer types in
vivo. Of the few studies that have addressed the sensitiv-
ity of cancer stem cells to TRAIL [16], the majority,
including medulloblastoma [56], glioblastoma [19] and
lymphoma [57]-derived stem cells, are resistant, with the
exception of colorectal cancer cell lines in which a FACS
sorted side-population was shown to be TRAIL respon-
sive [58]. Sensitization of cancer stem cells to TRAIL has
only previously been demonstrated in haematological
cancers, including AML [55] and T-cell lymphoma cells
[57], both of which have implicated, but not functionally
proven, a role for c-FLIP in the process. TRAIL sensitiza-
tion has not previously been described in solid tumour
stem cells. Our study, therefore, is the first demonstra-
tion, to our knowledge, of TRAIL-mediated loss of func-
tional stem cell activity in a solid tumour cell type and
the first indication that CSC activity is directly influenced
by c-FLIP.
Other mechanisms for targeting breast cancer stem cells
have been described. Notably, a recent study demonstrated
reduced stem cell activity in response to Notch1 or
Notch4 suppression using the same breast cancer cell lines
described herein [9], which supports the use of gamma-
secretase inhibitors in clinical trials [47]. The Akt/Wnt
pathway inhibitor, perifosine, reduces breast cancer stem
cell numbers [45] and incidentally is responsible for the
reduction in c-FLIP levels in AML stem cells [55]. Further-
more, it has been suggested that breast cancer stem cells
may selectively express HER2 [59,45]) and that inhibition
of this pathway could have beneficial consequences for
breast cancer patients with both HER2-positive and
HER2-negative disease [47,48]. As we have seen significant
responses of CSCs to combined FLIPi/TRAIL, indepen-
dent of HER2 receptor status, it will be of interest in the
future to establish whether primary human tumour stem
cell populations are equally susceptible and whether this is
due to amplification of a DISC-related mechanism.
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c-FLIP inhibition is, like TRAIL, a phenomenon that is
relatively cancer-specific. Analysis of non-transformed
mammary tissues from c-FLIP-deficient mice indicated
that the absence of c-FLIP was not detrimental to normal
tissue and did not sensitise normal tissue cells to TRAIL
induced apoptosis. It has not been established, however,
whether normal stem cells of the breast are affected by
either intervention. Neural progenitor cells are resistant to
TRAIL in a c-FLIP independent manner [60] and we are
currently investigating whether murine mammary stem
cells are similarly refractory.
Conclusions
Taken together our results demonstrate that c-FLIP is a
major inhibitor of TRAIL resistance in the tumour initiat-
ing (cancer stem) cell subset of a broad range of breast
cancer cell lines. This work suggests that targeting c-FLIP
may have important implications for the treatment of
breast cancer in conjunction with TRAIL based therapeu-
tics. Future studies are required, however, to address how
cancer stem cells and normal stem cells residing in their
respective niches in vivo would respond to FLIPi/TRAIL
based therapy.
Additional material
Additional file 1: Supplementary figures 1 to 8. Figure S1. Western
blot indicating parental cell line expression of epidermal growth factor
receptor 2 (ErbB2) and estrogen receptor alpha (ERa). Figure S2. A,
Representative flow cytometry plots and gating used to quantify dead
cells from treatments described in the methods and B, FLIPi = c-FLIP
siRNA. SCi = control siRNA. Figure S3. A, FLICE-Like Inhibitory Protein (c-
FLIP) mRNA expression of viable cell population following transfection
with siRNA. B, Western blot indicating relative c-FLIP protein expression
of viable cells following treatment with c-FLIP siRNA (FLIPi) or control
siRNA (SCi). C, Death receptor (DR)4 and DR5 expression in cell lines
following c-FLIP suppression by siRNA. Figure S4. A, Cell lines were
transfected with siRNA as previously described and apoptosis assessed by
flow cytometry using Annexin-V staining (eBioscience). B, Cells were
transfected with FLICE-Like Inhibitory Protein siRNA or scrambled control
siRNA, in the absence (FLIPi) or presence of the caspase inhibitors IETD
(caspase-8), LEHD (caspase-9) and AEVD (caspase-10) and apoptosis
assessed by flow cytometry staining for Annexin-V. Results indicate the
relative increase in Annexin-V staining of c-FLIP siRNA treated cells over
their corresponding control siRNA. Cell death by FLIPi was either partially
or completely inhibited by the IETD or AEVD demonstrating the cell
death induced was a caspase-8 or caspase-10 dependant mechanism
depending on cell line. LEHD also partially inhibited cell death in
selected lines, confirming a previous report that c-FLIP induced activation
of the extrinsic pathway impacted on the intrinsic apoptosis pathway.
Figure S5. A, Representative phase contrast images of cell death
analysed in Figure 2B. B, Cell lines were transfected with FLICE-Like
Inhibitory Protein siRNA (FLIPi) or scrambled control siRNA (SCi) stained
with PKH-26 (SCi) or PKH-67 (FLIPi), mixed at an equal ratio and treated
with or without 20 ng/ml of Tumour Necrosis Factor-Related Apoptosis
Inducing Ligand (TRAIL) for 18 hours. Cell death was then assessed by
flow cytometry separating SCi and FLIPi cell death based on the
membrane stain as in Figure 2B. Figure S6. Cells treated and quantified
as in Figure 4 using an alternative set of oligonucleotides for FLICE-Like
Inhibitory Protein (c-FLIP) targeted siRNA knockdown. Figure S7.
Representative flow cytometry plots and gating used in the analysis of
the aldefluor assay described in Figure 3C. Figure S8. A, Kaplen-Meier
plot demonstrating time taken for first detection of tumour as described
in Figure 5A. B, BT474 cells from Figure 5A were plated into
mammosphere culture conditions at a density of 20,000 cells/ml and
counted seven days later for percentage mammospheres (%MFU)
calculation. C, Quantification of cell number over the four-week adherent
culture period following Treatment 1 as described in Figure 5C.
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